Principia BioPharma's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Principia Biopharma is a developer of small molecule drugs for the treatment of cancer and inflammatory diseases.

Princip...
Read more

Based on data from Principia BioPharma's latest SEC filings

Annual Revenue

Based on data from Principia BioPharma's latest SEC filings

Employees

Martin Babler's photo - CEO of Principia BioPharma

CEO

Martin Babler

CEO Approval Rating

75/100

OVERVIEW

Founded:

2008

Headquarters:

South San FranciscoCalifornia

Status:

PublicIndependent Company of NASDAQPRNB

Industry Sector:

Biotechnology

SIC Code:

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Clovis Oncology a competitor of Principia BioPharma?

Want more news like this in your inbox? Get access for free

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

Innovimmune Biotherapeutics is seen as one of Principia BioPharma's top competitors. Innovimmune Biotherapeutics's headquarters is in New York, New York, and was founded in 2010. Like Principia BioPharma, Innovimmune Biotherapeutics also works within the Biotechnology industry. Innovimmune Biotherapeutics generates 2.50% of Principia BioPharma's revenue.

ASLAN Pharmaceuticals is one of Principia BioPharma's top rivals. ASLAN Pharmaceuticals was founded in 2010, and its headquarters is in Singapore, Other. Like Principia BioPharma, ASLAN Pharmaceuticals also works within the Biotechnology field. ASLAN Pharmaceuticals has NaN fewer employees than Principia BioPharma.

Akari is Principia BioPharma's #3 rival. Akari is a Public company that was founded in 2005 in London, England. Akari competes in the Pharmaceuticals industry. Compared to Principia BioPharma, Akari has 56 fewer employees.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Martin Babler

CEO

- -
69
$246.2M
$79.9M
1

Anderson Gaweco

President & CEO

70/100
3
- -
$2M
2

Dr Carl Firth

CEO

68/100
$142M
3

Clive Richardson

CEO

88/100
13
$90M
$ < 1M
4

Stephen F. Ghiglieri

Interim-CEO

70/100
6
$33.1M
$9.7M
5

Patrick J. Mahaffy

President & CEO

80/100
278
$763.3M
$119.2M
6

Sean McCarthy

President & CEO

88/100
78
$184.4M
$62.5M
7

Alexander Hardy

CEO

47/100
14,717
$100M
$18.3B
8

Scott Garland

President & CEO

84/100
163
$772M
$80.1M
9

CEO

- -
50,370
- -
$20B
10

Lee Babiss

CEO

87/100
3
$54M
$ < 1M

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$79.9M

Principia BioPharma's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 3.9B. Over the last four quarters, Principia BioPharma's revenue has grown by 61.6%. Specifically, in Q2 2019's revenue was $30M; in Q1 2019, it was $5.2M; in Q4 2018, it was $26.1M; in Q3 2018, Principia BioPharma's revenue was $18.6M.

Acquisitions

No recent acquisitions found related to Principia BioPharma

Principia BioPharma Funding History

Since Principia BioPharma was founded in 2008, it has participated in 6 rounds of funding. In total Principia BioPharma has raised $246.2M. Principia BioPharma's last funding round was on Aug 2018 for a total of $50.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Aug 2018
$50M
-
Equity
Jul 2015
$15.3M
Series B
Apr 2014
$50M
Series A
Oct 2012
$12.5M
Equity
Feb 2011
$12.1M

Total Funding: $246.2M

Since Principia BioPharma was founded in 2008, it has participated in 6 rounds of funding. In total Principia BioPharma has raised $246.2M. Principia BioPharma's last funding round was on Aug 2018 for a total of $50.0M

Investments

No recent investments found related to Principia BioPharma

Principia BioPharma News

August 27, 2019Benzinga

Principia to Present at the 2019 Baird Global Healthcare Conference and the Wells Fargo Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB)... See more »
June 2, 2019Zolmax News

$8.00 Million in Sales Expected for Principia Biopharma Inc (PRNB) This Quarter

Wall Street analysts forecast that Principia Biopharma Inc (NASDAQ:PRNB) will post $8.00 million in s... See more »
May 8, 2019Finance Daily

Principia Biopharma (NASDAQ:PRNB) and Its Rivals

Principia Biopharma (NASDAQ: PRNB) is one of 553 publicly-traded companies in the "Pharmaceutical pre... See more »
April 18, 2019FirstWord Pharma

Principia Biopharma Appoints Shao-Lee Lin, M.D., Ph.D. to Board of Directors

Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing... See more »
March 11, 20194-traders

, AbbVie End Oral Immunoproteasome Collaboration

(marketscreener.com) By Colin Kellaher Principia Biopharma on Monday said it is ending its collaborat... See more »
March 11, 2019pipelinereview

Principia Biopharma Reacquires Rights to Oral Immunoproteasome Program

SOUTH SAN FRANCISCO, CA, USA I March 11, 2019 I Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage... See more »
March 4, 2019StreetInsider

Principia Biopharma Inc. (PRNB) Highlights Positive Data from Phase 2 Pemphigus Vulgaris Trial at AAD Meetings

Principia Biopharma Inc. (NASDAQ: PRNB) today announced Phase 2 clinical data from the Believe-PV stu... See more »

Principia BioPharma Press Releases

May 14, 2019GlobeNewswire

Principia Biopharma Announces First Patient Dosed in Sanofi's Phase 2b Trial of SAR442168 in Multiple Sclerosis, Triggering $30 Million Milestone

SOUTH SAN FRANCISCO, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB)... See more »
May 9, 2019GlobalNewswire

Principia Biopharma to Present at the 2019 Bank of America Merrill Lynch Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB)... See more »
May 7, 2019GlobeNewswire

Principia Biopharma Reports First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB)... See more »
May 7, 2019StreetInsider

Principia Biopharma Reports First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB)... See more »
March 20, 2019GlobeNewswire

Principia Biopharma Reports Fourth Quarter and Full Year 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRN... See more »
March 1, 2019GlobeNewswire

Principia Biopharma Presents Phase 1 Clinical Data from CNS Penetrating BTK Inhibitor Candidate PRN2246/SAR442168 at ACTRIMS 2019

-- Orally administered PRN2246 achieved full BTK occupancy in peripheral blood ---- PRN2246 exhibited... See more »
February 22, 2019GlobeNewswire

Principia Biopharma Announces the Acceptance of Data from Phase 2 Pemphigus Vulgaris Trial as a Late-Breaking Presentation at 2019 American Academy of Dermatology Meeting

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB... See more »

Principia BioPharma Videos

Headquarters

400 East Jamie Court Suite 302

South San Francisco, California94080

650-416-7700

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Principia Biopharma is a developer of small molecule drugs for the treatment of cancer and inflammatory diseases. Principia BioPharma was founded in 2008. Principia BioPharma's headquarters is located in South San Francisco, California, USA 94080. It ...

CEO

Principia BioPharma's CEO, Martin Babler, currently has an approval rating of 75%. Principia BioPharma's primary competitors are Innovimmune Biotherapeutics, ASLAN Pharmaceuticals & Akari.

Website

principiabio.com

Frequently Asked Questions about Principia BioPharma

  1. When was Principia BioPharma founded?

    Principia BioPharma was founded in 2008
  2. Who is Principia BioPharma's CEO?

    Principia BioPharma's CEO is Martin Babler
  3. How much revenue does Principia BioPharma generate?

    Principia BioPharma generates $79.9M in revenue
  4. How much funding does Principia BioPharma have?

    Principia BioPharma has historically raised $246.2M in funding
  1. Where is Principia BioPharma's headquarters?

    Principia BioPharma's headquarters is in South San Francisco California, USA
  2. How many employees does Principia BioPharma have?

    Principia BioPharma has 69 employees
  3. What sector does Principia BioPharma operate in?

    Principia BioPharma is in Biotechnology
  4. Who are Principia BioPharma's competitors?

    Principia BioPharma's top competitors are Innovimmune Biotherapeutics, ASLAN Pharmaceuticals, Akari